Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Manual for Electric Vehicles that will be hot dealers in 2023 - 2She just became the first wheelchair user to travel to space
- 3Putin says Russian forces will seize capital of Zaporizhzhya
- 4As tetanus vaccination rates decline, doctors worry about rising case numbers
- 5Putting resources into Yourself: Self-awareness Techniques
- 6 Novice Cameras for 2024: Ideal for New Picture takers
- The Electric Bicycle Americans Can Confide in 2024
- Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
- Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
- Really focusing on Succulents: Tips and Procedures
- More parents refusing vitamin K shots for newborns, study finds
- Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
- Investigate Business Mastercard Choices for Better Rewards and Rewards
- Vinicultural Investigation: A Survey of \Enjoying Fine Vintages\ Wine sampling
